BOSTON, May 24, 2017 /PRNewswire/ -- HVH Precision Analytics (HVH), a company specializing in the use of advanced analytics to identify and connect biopharma companies with patients and providers, today announced it will present findings based on use of big data analytics for early diagnosis of amyotrophic lateral sclerosis (ALS) at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Boston.
Using its three-stage proprietary methodology, HVH was able to collect, aggregate and analyze the journeys of known ALS patients, helping to inform assessment of early indicators of potential disease. The advanced machine learning techniques uncovered potential signals in ALS patients' claims histories that appear to differentiate them from the general population up to five years before the initial ALS diagnosis. MT Pharma America, Inc. conceptualized and supported the data analytics research being presented and will continue to collaborate with HVH on the clinical interpretation and application of the findings.
ALS is a rapidly progressive, incurable disease that affects the nerve cells (neurons) in the brain and spinal cord that control voluntary muscle movement.[i] The majority of patients with ALS die within two to five years of diagnosis.[ii] Initial symptoms can be subtle at first, and it can take 12 to 14 months to be accurately diagnosed with ALS.[iii], [iv]
"Tremendous progress has been made in the field of data analytics and predictive modeling to help better understand undiagnosed patients," said Tara Grabowsky, M.D., Chief Medical Officer, HVH. "This is an example of how the intensive analysis capabilities of the HVH platform can potentially identify early signals in ALS that could ultimately be used to develop earlier diagnostic tools. Given the rapid and debilitating nature of this horrible disease, this is an important step forward."
- Big Data Analytics for Early Diagnosis of Amyotrophic Lateral Sclerosis (ALS)
PRM45, B20, Wednesday, May 24, 8:00 a.m. – 1:30 p.m. ET
For details on these findings, please contact firstname.lastname@example.org.
HVH is a joint venture built on the partnership between Havas Health, a strategic communications partner to many top biopharma companies, and Vencore, a leader in next-gen machine learning and advanced predictive analytics. HVH has offices in Boston, New York, and King of Prussia, Pennsylvania. For information on our validated methodology please visit https://www.hvhprecision.com/views/publication/. For more general information, please visit www.hvhprecision.com
About MT Pharma America
Based in Jersey City, N.J., MT Pharma America is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in the U.S. It was established by MTPC to commercialize approved pharmaceutical products in the U.S. with plans to expand its product line through collaborations with partners. For more information, please visit www.mt-pharma-america.com or follow us on Twitter at https://twitter.com/MTPharmaUS.
[i] National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet. Accessed May 22, 2017.
[ii] Mehta P, Kaye W, Bryan L, et al. (2016). Prevalence of Amyotrophic Lateral Sclerosis — United States, 2012–2013. MMWR Surveill Summ; 65(No. SS-8):1–12.
[iii] ALS Therapy Development Institute. What is ALS? http://www.als.net/what-is-als/. Accessed April 17, 2017.
[iv] Brooks BR. (2000). Risk factors in the early diagnosis of ALS: North American epidemiological studies. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1:sup1, S19-S26.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hvh-precision-analytics-to-present-data-on-early-diagnosis-of-amyotrophic-lateral-sclerosis-at-international-society-for-pharmacoeconomics-and-outcomes-research-ispor-22nd-annual-international-meeting-300463008.html